Ligand Pharmaceuticals (LGND) EPS (Basic) Growth (3y) (2013 - 2026)
Ligand Pharmaceuticals (LGND) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 64.84% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.21% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.99% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -38.31% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.73% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.51% |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -90.18% |
| Dec 31, 2025 | 147.92% |
| Sep 30, 2025 | 134.81% |
| Jun 30, 2025 | 32.26% |
| Mar 31, 2025 | -147.46% |
| Dec 31, 2024 | -133.41% |
| Mar 31, 2023 | 59.42% |
| Dec 31, 2022 | 23.30% |
| Sep 30, 2022 | 12.35% |
| Jun 30, 2022 | -2.76% |
| Mar 31, 2022 | -26.09% |
| Dec 31, 2021 | 59.47% |
| Sep 30, 2021 | -28.55% |
| Jun 30, 2021 | -28.05% |
| Mar 31, 2021 | -28.72% |
| Mar 31, 2019 | 739.90% |
| Dec 31, 2018 | -102.18% |
| Sep 30, 2018 | -31.74% |
| Mar 31, 2016 | 79.81% |
| Jun 30, 2013 | 733.97% |